Piper Sandler raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $65 from $62 and keeps an Overweight rating on the shares following the on-time FDA approval for Dawnzera in hereditary angioedema in adult and pediatric patients 12 and over. The label is largely in-line with expectations, and Piper is encouraged by the company’s commentary around the experienced sales team in allergy and immunology and other commercial preparations, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals price target raised to $69 from $65 at Citi
- Ionis Pharmaceuticals price target raised to $82 from $77 at Wells Fargo
- Ionis Pharmaceuticals price target raised to $58 from $57 at Barclays
- Ionis Pharmaceuticals price target raised to $64 from $63 at BofA
- Ionis Pharmaceuticals’ Dawnzera: A Promising New Entrant in HAE Treatment with Strong Market Potential